A PHASE I STUDY OF A COMBINATION OF YTTRIUM-90 LABELED HUMANIZED ANTI-CEA M5A

YTTRIUM-90 标记的人源化抗 CEA M5A 组合的 I 期研究

• 批准号: 7982078
• 负责人: JEFFREY Y WONG
• 金额: $ 2.09万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982078
• 关键词: 90Y; Anti-CEA Antibody; Antibodies; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Label; Maximum Tolerated Dose; Phase I Clinical Trials; Radioimmunoconjugate; Research; Research Personnel; Resources; Source; Therapeutic Agents; United States National Institutes of Health; chemotherapy; gemcitabine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I trial will evaluate the therapeutic agent Y-90-M5A-humanized anti-CEA antibody in combination with Gemcitabine chemotherapy. It will define the maximum tolerated dose of the radiolabeled antibody in combination with Gemcitabine. In addition, immunogenecity of the antibody will be assessed.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 I 期试验将评估治疗剂 Y-90-M5A 人源化抗 CEA 抗体与吉西他滨化疗的组合。 它将定义放射性标记抗体与吉西他滨组合的最大耐受剂量。 此外，还将评估抗体的免疫原性。